BioNTech

(IN BRIEF) Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older. Pending final approval from the European Commission, the vaccine will … Read the full press release →

(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release →

(IN BRIEF) BioNTech and Duality Biologics have announced the commencement of a pivotal Phase 3 trial for BNT323/DB-1303, a next-generation antibody-drug conjugate (ADC) targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in metastatic breast cancer. The trial will enroll … Read the full press release →

(IN BRIEF) BioNTech and Duality Biologics have received Breakthrough Therapy designation from the FDA for their antibody-drug conjugate (ADC) candidate, BNT323/DB-1303. The designation is for the treatment of advanced endometrial cancer in patients who have progressed following immune checkpoint inhibitor … Read the full press release →

(IN BRIEF) BioNTech has achieved a significant milestone in expanding mRNA vaccine manufacturing in Africa with the inauguration of its Kigali site, which includes the first manufacturing unit known as BioNTainer. This move is part of BioNTech’s broader efforts to … Read the full press release →

(IN BRIEF) BioNTech, a leading biotechnology company, has formalized a multi-year strategic partnership with the State of Victoria in Australia, building upon a prior Letter of Intent established in October 2022. The collaboration aims to strengthen the local mRNA ecosystem … Read the full press release →

(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine program for influenza and COVID-19. The lead formulations showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. … Read the full press release →

(IN BRIEF) BioNTech SE is set to reveal its financial results for the third quarter of 2023 on November 6th, 2023. The company invites investors and the public to participate in a conference call and webcast at 8:00 a.m. ET … Read the full press release →

(IN BRIEF) BioNTech will be presenting updates on multiple programs across its oncology pipeline at the European Society for Molecular Oncology (ESMO) Congress 2023. These updates include data on investigational CAR-T and ex-vivo T cell therapies, a novel ADC (antibody-drug … Read the full press release →

(IN BRIEF) BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to develop an mRNA-based vaccine, BNT166, for the prevention of mpox (formerly monkeypox), an infectious disease that can have severe and life-threatening complications. … Read the full press release →

(IN BRIEF) The European Union Commission has given the green light for the use of the adapted Comirnaty XBB.1.5 COVID-19 vaccine, developed by BioNTech-Pfizer, in Member States’ upcoming fall vaccination campaigns. This marks the third adaptation of the Comirnaty vaccine … Read the full press release →

(IN BRIEF) Pfizer and BioNTech have received a recommendation for marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. The recommendation includes the administration of a single … Read the full press release →

(IN BRIEF) BioNTech SE, a biopharmaceutical company, has appointed James Ryan as Chief Legal Officer (CLO) and a member of the Management Board, effective from September 1, 2023. In this role, Ryan will oversee the company’s corporate legal strategy, global … Read the full press release →

(IN BRIEF) BioNTech reported its second-quarter 2023 financial results and corporate update, highlighting significant pipeline advancements in oncology with the initiation of BNT316/ONC-392 Phase 3 pivotal trial and positive data updates across multiple technology platforms. The company also prepares for … Read the full press release →

(IN BRIEF) BioNTech SE has completed the acquisition of InstaDeep Ltd., a prominent AI and ML technology company. The acquisition is part of BioNTech’s strategy to enhance AI-driven drug discovery and develop advanced immunotherapies and vaccines for diseases with significant … Read the full press release →

(IN BRIEF) BioNTech and OncoC4 have entered into an exclusive license and collaboration agreement to develop and commercialize OncoC4’s anti-CTLA-4 monoclonal antibody candidate, ONC-392. The candidate aims to delete immunosuppressive T cells in the tumor microenvironment but spare T cells … Read the full press release →

Siemens prend la cinquième place du classement des brevets de l’Office européen des brevets Vingtinventions par jour ouvrable au cours de l’exercice 2021 Forte croissance des technologies pour l’Internet Industriel des Objets Le magazine économique américain Fast Company reconnaît Siemens … Read the full press release →

Siemens takes fifth place in European Patent Office’s patent ranking Twentyinventions per working day in fiscal 2021 Strong growth in technologies for the Industrial Internet of Things U.S. business magazine Fast Company recognizes Siemens as one of world’s most innovative … Read the full press release →